These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21748869)

  • 1. The long Avandia endgame.
    Mullard A
    Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
    [No Abstract]   [Full Text] [Related]  

  • 2. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
    Califf RM; Kramer JM
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):782-6. PubMed ID: 18655016
    [No Abstract]   [Full Text] [Related]  

  • 3. After Avandia, some seek split in drug approval and monitoring.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
    [No Abstract]   [Full Text] [Related]  

  • 4. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
    Rosen CJ
    N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosiglitazone and implications for pharmacovigilance.
    Kazi D
    BMJ; 2007 Jun; 334(7606):1233-4. PubMed ID: 17569897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avandia outcome may signal change in epidemiologists' sway.
    Wadman M
    Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526293
    [No Abstract]   [Full Text] [Related]  

  • 8. Rosiglitazone and cardiovascular risk.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
    [No Abstract]   [Full Text] [Related]  

  • 9. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

  • 10. The record on rosiglitazone and the risk of myocardial infarction.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
    [No Abstract]   [Full Text] [Related]  

  • 11. Rosiglitazone: a case of regulatory hubris.
    Nissen SE
    BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone and the FDA.
    Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
    N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA committee urges tight restrictions on rosiglitazone.
    Roehr B
    BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
    [No Abstract]   [Full Text] [Related]  

  • 14. Alternative medications exist for controversial diabetes drug. Patients concerned about rosiglitazone (Avandia) should talk with their doctors about other options.
    Heart Advis; 2010 Oct; 13(10):4. PubMed ID: 23189348
    [No Abstract]   [Full Text] [Related]  

  • 15. Rosiglitazone and the FDA.
    Krall RL
    N Engl J Med; 2007 Oct; 357(17):1776-7; author reply 1777. PubMed ID: 17969232
    [No Abstract]   [Full Text] [Related]  

  • 16. The truth about rosiglitazone (avandia).
    Ledbetter C; Laustsen G
    Nurse Pract; 2008 Jun; 33(6):10-1. PubMed ID: 18528195
    [No Abstract]   [Full Text] [Related]  

  • 17. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone: failure of oversight or demons imagined?
    Susman J
    J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
    [No Abstract]   [Full Text] [Related]  

  • 19. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 20. [What about the controversy regarding rosiglitazone].
    Scheen AJ; De Flines J; Paquot N
    Rev Med Liege; 2007 Sep; 62(9):560-5. PubMed ID: 17966792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.